FDA announced yesterday its intent to green light hydroxychloroquine compounding by outsourcing facilities, as long as compliance with FD&C Act requirements is achieved.  I’m not a compounding expert, but even a lay person can envision the threat of economically motivated adulteration (EMA) increasing dramatically as global demand for these APIs skyrockets.  The 2008 heparin incident is a potent reminder that enhanced due diligence measures and product testing protocols are crucial when API supply disruptions favorable to EMA schemes are known to exist. The 2006 Panamanian diethylene glycol incident is another EMA tragedy. Both of these deadly supply chain incursions spawned prolific human suffering and originated in China. As I wrote in June 2013, “Compounding pharmacies that may be importing APIs from unregulated chemical companies in China represent a gaping hole in our supply chain, one that exposes patients everywhere to risks associated with potentially unsafe and adulterated APIs intended for pharmacy compounding.”